Addex Therapeutics (ADXN) EBIT Margin (2022 - 2025)
Historic EBIT Margin for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to 2342.13%.
- Addex Therapeutics' EBIT Margin fell 11864200.0% to 2342.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 4217.87%, marking a year-over-year decrease of 34010700.0%. This contributed to the annual value of 681.82% for FY2024, which is 5427600.0% down from last year.
- Latest data reveals that Addex Therapeutics reported EBIT Margin of 2342.13% as of Q3 2025, which was down 11864200.0% from 12575.46% recorded in Q2 2025.
- Addex Therapeutics' EBIT Margin's 5-year high stood at 12575.46% during Q2 2025, with a 5-year trough of 182692.31% in Q4 2024.
- Over the past 4 years, Addex Therapeutics' median EBIT Margin value was 1017.78% (recorded in 2022), while the average stood at 12534.09%.
- As far as peak fluctuations go, Addex Therapeutics' EBIT Margin crashed by -1812306000bps in 2024, and later surged by 133574800bps in 2025.
- Quarter analysis of 4 years shows Addex Therapeutics' EBIT Margin stood at 3463.7% in 2022, then skyrocketed by 58bps to 1461.7% in 2023, then plummeted by -12399bps to 182692.31% in 2024, then soared by 99bps to 2342.13% in 2025.
- Its EBIT Margin was 2342.13% in Q3 2025, compared to 12575.46% in Q2 2025 and 672.09% in Q1 2025.